MandalMed is a privately-held company focused on modulation of glycobiology and innate immunity to develop treatments for organ fibrosis. The initial target is galectin-3, one of a family of carbohydrate binding proteins. The lead product is MM-003, a protein inhibitor of galectin-3, for prevention and reversal of fibrosis after myocardial infarction and in heart failure.
Khalid Mounzih, Ph.D.
VP, Product Development
Dr. Mounzih formerly had product development positions at notable Bay Area biotech companies including Zymed, Megbios, Elan Pharmaceuticals, and Predicant Biosciences, and also held a research appointment at UCSF.
Dr. Catherine Polizzi of Morrison & Foerster
Founded in San Francisco in 1883, the IP practice of Morrison & Foerster regularly ranks as one of the top in the US. Dr. Catherine Polizzi, a partner in Palo Alto, represents MandalMed. Catherine was inducted to the Legal Media Group’s Life Sciences Hall of Fame in 2018 for her achievements in the life sciences field. She is engaged in some of the most high-profile matters in the pharmaceutical and biotech sectors.
Mr. Gregory Porter, C.P.A., of Silverman, Krantz, & Porter
Gregory Porter of Silverman, Krantz, and Porter in San Francisco has performed accounting services for MandalMed since the Company was founded. Silverman, Krantz, and Porter offers a wide range of services to individual and business clients that benefit by receiving personalized, quality services.
Robert R. Rugani, J.D., of Acceleron Law Group
Robert Rugani, partner and co-founder of Acceleron Law Group, provides corporate legal services to MandalMed. Robert’s practice focuses on emerging growth and mid-cap companies. Previously a partner at Fortis General Counsel, Robert also is an Adjunct Professor of Law at the USC Gould School of Law.